Summary by Futu AI
Biora Therapeutics, Inc. has updated its prospectus supplement, which now supersedes certain information from the original prospectus dated December 29, 2023. The update pertains to the offering of a significant number of shares of common stock related to various financial instruments. Specifically, the offering includes shares issuable upon conversion of convertible senior secured notes due in 2028, shares potentially issuable for interest payments or make-whole amounts on these notes, and shares issuable upon the exercise of different sets of warrants with varying exercise prices and terms. Additionally, Biora Therapeutics has entered into a Warrant Amendment Agreement on March 31, 2024, with an institutional investor to amend the terms of the Commitment Warrants. The amendments include a reduction in the exercise price to $1.10 per share...Show More